• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Economic burden of skin cancer in Southern Iran: A cost-of-illness study.

作者信息

Jalali Faride Sadat, Keshavarz Khosro, Seif Mozhgan, Jafari Abdosaleh, Ravangard Ramin

机构信息

Student Research Committee, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

Health Human Resources Research Centre, School of Health Management and Information Sciences, Shiraz University of Medical Sciences, Shiraz, Iran.

出版信息

J Cancer Policy. 2025 Sep;45:100602. doi: 10.1016/j.jcpo.2025.100602. Epub 2025 May 27.

DOI:10.1016/j.jcpo.2025.100602
PMID:40441483
Abstract

BACKGROUND

Skin cancer is one of the most common cancers around the world, which imposes a great economic burden on patients and societies. The present study aimed at determining the economic burden of skin cancer in patients referred to diagnostic and treatment centers in southern Iran in 2021.

METHODS

This was a partial economic evaluation of the cost-of-illness type conducted from the societal perspective with the bottom-up and prevalence-based approaches. A total of 108 patients were included through the simple random sampling method, and a researcher-made data collection form was used to collect the required data. The data on direct medical costs were obtained by using the patient's medical and financial records, as well as the data on direct medical and indirect costs were collected by asking the patients or their companions on the phone.

RESULTS

The results showed that the annual cost of each skin cancer patient in the studied sample was 7699.76 USD in 2021. The indirect costs accounted for the largest share of costs (72.85 %), of which the costs of premature death were the highest. The costs of direct medical and direct non-medical costs were 19.77 % and 7.38 %, respectively, and the economic burden of the disease in the country was estimated at 569,550,508 USD in that year.

CONCLUSIONS

The economic burden of skin cancer in Iran is very high. Some suggestions to reduce its costs and economic burden include providing specialized services in high-incidence cities, virtual follow-ups, screening services, and sun safety interventions.

摘要

相似文献

1
Economic burden of skin cancer in Southern Iran: A cost-of-illness study.
J Cancer Policy. 2025 Sep;45:100602. doi: 10.1016/j.jcpo.2025.100602. Epub 2025 May 27.
2
Economic Burden of Major Depressive Disorder (MDD), Panic Anxiety, and Generalized Anxiety Disorder (GAD).重度抑郁症(MDD)、惊恐焦虑症和广泛性焦虑症(GAD)的经济负担。
J Ment Health Policy Econ. 2025 Jun 1;28(2):51-58.
3
Economic burden of hypertension in Iran: a prevalence-based cost of illness study.伊朗高血压的经济负担:一项基于患病率的疾病成本研究。
BMJ Open. 2025 Jun 8;15(6):e099322. doi: 10.1136/bmjopen-2025-099322.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
The economic burden of breast cancer in western Iran: a cross-sectional cost-of-illness study.伊朗西部乳腺癌的经济负担:一项横断面疾病成本研究。
J Health Popul Nutr. 2025 Jan 22;44(1):16. doi: 10.1186/s41043-025-00738-0.
6
Economic burden of urgency urinary incontinence in the United States: a systematic review.美国急迫性尿失禁的经济负担:一项系统评价
J Manag Care Pharm. 2014 Feb;20(2):130-40. doi: 10.18553/jmcp.2014.20.2.130.
7
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.对紫杉醇、多西他赛、吉西他滨和长春瑞滨在非小细胞肺癌中的临床疗效和成本效益进行的快速系统评价。
Health Technol Assess. 2001;5(32):1-195. doi: 10.3310/hta5320.
8
Economic burden of breast cancer in India, 2000-2021 and forecast to 2030.2000 - 2021年印度乳腺癌的经济负担及到2030年的预测
Sci Rep. 2025 Jan 8;15(1):1323. doi: 10.1038/s41598-024-83896-1.
9
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
10
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.